UniQure (QURE) Reports Positive Phase I/IIa AMT-191 Data for Fabry Disease, Shows Sustained Enzyme Activity
UniQure (NASDAQ:QURE) is one of the most promising low-cost stocks to buy now. On February 6, UniQure reported positive updated data from its Phase I/IIa trial of AMT-191, which is a gene therapy for Fabry disease. All 11 patients across three different dose levels showed increased enzyme activity, with the longest-treated patient maintaining these high levels for over a year. Notably, the enzyme levels were significantly above normal ranges, showing a clear relationship between the dose received and the amount of enzyme produced.
The treatment allowed 6 out of the 11 patients to stop their regular enzyme replacement therapy/ERT after meeting specific clinical criteria. Even after stopping ERT, patients maintained stable levels of lyso-Gb3, the toxic substance that typically builds up in Fabry disease. This suggests that the one-time gene therapy could potentially replace the need for lifelong, bi-weekly infusions for some patients.
While the therapy shows promise, UniQure has paused new dosing in the mid- and high-dose groups to evaluate some safety findings. Two patients in the middle dose group experienced high liver enzyme levels that were classified as dose-limiting toxicities, though both responded to steroid treatment. Other previously reported serious events in the high-dose group included chest pain and a stroke, though some were determined to be unrelated to the study drug.
UniQure (NASDAQ:QURE) develops treatments for patients suffering from rare and other devastating diseases in the US.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Gold falls below $4,000, yen rises to resistance level, market becomes picky about 'safe-haven assets'
Gold fell below $4,000 this week, hitting a three-month low, diverging from US Treasury yields despite heightened global risk aversion. Analysts attribute gold's weakness to the fading speculative sentiment over the past year and rising expectations of interest rate hikes. Meanwhile, the yen, with its 40% undervaluation, has become Goldman Sachs' top choice as a hedging tool, quietly reshaping the landscape of traditional safe-haven assets.
A respite after a week of crisis! France temporarily escapes Moody's downgrade
Moody's has maintained France's rating, the second-largest economy in the Eurozone, at Aa3, which is seven notches above "junk" status and on par with the UK's rating; the outlook remains negative.
No Downgrade! Moody's Didn't "Add Fuel to the Fire", France "Dodged a Bullet"
Moody's announced it will maintain France's Aa3 rating, stating that France's diversified economic structure and robust public institutions support the current rating. However, the outlook remains negative because political instability will continue to constrain fiscal consolidation efforts. Moody's added that the maintenance of the Aa3 rating is based on the assumption that France will ultimately implement a deficit reduction plan, and expects "financing costs and social tensions will ease in the coming months."
The U.S. repo market faces a major test with new clearing regulations in 2027! CIBC warns: Insufficient market preparation may trigger interest rate volatility
Strategists at the Canadian Imperial Bank of Commerce have warned that as the deadline for mandatory central clearing of U.S. Treasury repo transactions approaches, market participants' preparation progress remains sluggish. This could lead financial institutions to concentrate their compliance adjustments by the end of June 2027, potentially disrupting market pricing and financing capacity, and driving repo rates to rise temporarily.
Crypto prices
More
